Loading...
ELCC congress 20222025-01-28T17:15:37+01:00

ELCC 2022

Lecture Board: Maximilian Hochmair, MD; Jordi Remon, MD, PhD; Fred R. Hirsch, MD, PhD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from ELCC 2022

ELCC 2022 English

Full report (english)

EXPERT VIDEOS

All video interviews from ELCC 2022

Jordi Remon outlines what needs to be considered in the context of neoadjuvant and adjuvant immunotherapy in patients with resectable lung cancer, how tyrosine kinase inhibitors can contribute to effective perioperative treatment, treatment approaches in patients with oncogene-driven lung cancer who develop brain metastases as well as in patients with CNS affection whose tumors do not harbor genetic drivers. Current challenges in selecting the best immunotherapeutic approach for the individual patient with mNSCLC and how to deal with them as well as promising potential predictive biomarkers of ICI in patients with NSCLC are highlighted, too.

Lizza Hendriks discusses how clinical trials should be adapted considering the increasing use of brain metastasis screening in lung cancer patients, the immune micro-environment of CNS metastases, the role of the treatment sequence in the management of patients with brain lesions and summarizes how patients with low PD-L1 expression, frail/elderly patients and those with actionable mutations can be addressed, followed by depicting novel biomarkers for precision immunotherapy. 

Jarushka Naidoo depicts recent developments in the first-line therapy of limited-stage small cell lung cancer (SCLC), treatment options for patients with newly diagnosed extensive-stage SCLC, agents emerging for the management of patients with platinum-refractory disease, the molecular types of SCLC and how they respond to targeted therapies and ICIs and gives an overview of the greatest difficulties in the field of irAEs. 

At this year’s conference, which took place in Geneva from 10th to 13th April, more than 120 speakers shared their knowledge with around 1,600 delegates from 75 countries. The comprehensive program that included a wide range of session types and the presentation of 210 abstracts aimed at conveying a broad view of the current knowledge ranging from screening and the very early disease to current and potential future treatment approaches for different types of thoracic tumors.

Pilar Garrido • MD • PhD, Head of the Thoracic Tumor Section, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
Go to Top